- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Howard Burris Discusses Simultaneous Approvals of Novel Therapies, Diagnostics
With a biomarker attached, the odds of a drug being approved goes up from about 10% to greater than 25%, explained Howard A. "Skip" Burris, III, MD, FACP, FASCO, president, clinical operations, and chief medical officer of Sarah Cannon Research Institute.
With a biomarker attached, the odds of a drug being approved goes up from about 10% to greater than 25%, explained Howard A. "Skip" Burris, III, MD, FACP, FASCO, president, clinical operations, and chief medical officer of Sarah Cannon Research Institute.
Transcript
When the FDA approved atezolizumab for the treatment of triple-negative breast cancer, it also approved the VENTANA PD-L1 assay. Do you think simultaneous approvals like this will be a trend in the future?
I do think that we’re going to see more and more of the development of the biomarker along with the individual cancer therapy. There’s some data that’s been published recently that has been talked about that shows that if a biomarker is part of your clinical development strategy, you have a much greater chance of approval. We know that many drugs come out of the phase 1 setting and don’t make it through the whole approval process, but with a biomarker attached, the odds of that drug being approved go up from about 10% to greater than 25%. So, identifying the patients that are most likely to benefit, I think, will be key, and it’s nice to see the FDA working with pharma to in fact promote this kind of strategy.
New Insights Into Meth-Associated PAH Care Gaps: Anjali Vaidya, MD, on Closing the Divide
June 4th 2025Research from Anjali Vaidya, MD, FACC, FASE, FACP, Temple University Hospital, reveals critical care gaps for patients with methamphetamine-associated pulmonary arterial hypertension (PAH), emphasizing the need for early diagnosis and integrated support.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD
April 25th 2025When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.
Read More
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
